Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.
about
Human family with sequence similarity 60 member A (FAM60A) protein: a new subunit of the Sin3 deacetylase complexHistone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyCurrent status and future prospects for epigenetic psychopharmacologyHDAC inhibitors and immunotherapy; a double edged sword?Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.Romidepsin: in the treatment of T-cell lymphoma.Panobinostat in lymphoid and myeloid malignancies.Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.HBx induces hypomethylation of distal intragenic CpG islands required for active expression of developmental regulatorsJuvenile myoclonic epilepsy with multiple sclerosis: is there a dual role for valproate?Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.The nuclear envelope environment and its cancer connections.STAT1 signaling is not regulated by a phosphorylation-acetylation switchNBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity.RNA polymerase II pausing can be retained or acquired during activation of genes involved in the epithelial to mesenchymal transition.Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor responseHistone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer.Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis.Lysine acetylation: elucidating the components of an emerging global signaling pathway in trypanosomes.Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.Profile of panobinostat and its potential for treatment in solid tumors: an update.Epigenetics-beyond the genome in alcoholism.HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.Romidepsin in the treatment of T-cell lymphoma: profile report.HDAC inhibitors in HIV.Epigenetic mechanisms as targets and companions of viral assaults.Targeting class I histone deacetylases in cancer therapy.Current trends in epigenetic drug discovery.Targeting histone deacetylase in thyroid cancer.Romidepsin for peripheral T-cell lymphoma.Emerging drugs for T-cell lymphoma.Epigenetics in the hematologic malignancies.Antigen-specific T cell therapies for cancer.
P2860
Q24298824-F669F8E9-AF30-4B60-865F-3437125E3DBAQ26783032-5E19D94F-D692-4ED4-96D2-984AC0C0D8ABQ26825053-28E8E633-1010-4D19-B262-155FC7B7C236Q26825464-936D390A-5CB3-474B-8356-5B53BF916A0BQ26853102-822D39C9-34BE-475B-B3AF-330AE2385722Q30424831-1F88A3F4-A75A-451C-8EF3-B7886AB6117CQ33396519-76F79BF5-5527-4B3A-9DD6-72283BC76B3CQ33408889-13D3FA64-DE2A-4795-811B-2346FB81FC62Q33838633-55331D18-9FBC-4661-9004-3BF8319ED5F8Q33853890-2F3220D7-3F8F-49FF-9CFE-1F247D7700E9Q33878817-F2AC3BE6-F1AA-4D0B-8AD2-318ED737B28DQ33983255-B8FE31EC-2F0E-4E5F-9D4D-F6F612E373BFQ34101029-7FAB0E58-A1E7-4977-B94C-13A36138C2CAQ34224278-CB0E1F30-67DA-47FB-898A-1CAF2AA159ECQ34254678-CEA3EC76-0539-470B-87A2-86811F895D61Q35096677-CA8825AC-E8FF-4FC2-A97B-8DAF258D3ACBQ35419727-EE1B368D-BC65-4683-B4C9-397AC4A84D39Q35562114-87095240-F0F9-41C3-9852-02A23C2ED428Q35741605-0C8033DC-44B3-4D57-9F0C-0EA186E9CC49Q35856816-816D91CC-DC83-4AC2-B120-1E01693ACE8FQ35879608-A053F8D0-BE50-4FD1-8EEF-A3C13015FB70Q35998436-C7E3CF34-ABD4-40D1-8094-E2721E9CAD20Q36063233-3C0B1A40-74F4-421A-8F24-47176EEEB41BQ36217335-6DE1D779-F434-4DC1-9776-A578CE1B58E0Q36316016-3D75C5E3-BCF5-419F-9B3B-6EDC2EED3DEEQ37030911-999CB5AE-DE2F-417F-A0C5-82BE1B99EA9FQ37073624-C5F4A543-CE83-457C-9F40-A6ED09FC1E2FQ37324186-E3FD7C1B-BC84-42B4-AACE-7BCAF8CB00BDQ37386414-10E6AF4A-78DA-424C-B98B-A6E6090F24D9Q37949185-34350718-8342-4FF2-9FF0-66615C8F71CBQ37952288-B39EFC91-9E02-4A36-8D15-19CEC79162E4Q37956178-1B9A0FC9-4826-449C-81A8-AE1E95F4CEF0Q37993608-0C1916D5-90C0-4CA4-B243-7BBAA0A66A4DQ38051736-95F46C12-83BE-4863-A00A-0E65AE848F76Q38060183-BC76BEB6-F950-46E8-B44A-00462C8EB30EQ38066990-3B5EF72A-9346-49FB-BDBF-7B25AA9E9D65Q38132813-80CF64FE-8850-498A-9317-75FD7207B2B7Q38196943-3F7AD391-B118-48CB-84B9-BF13FAB37137Q38282809-B78CE3BF-2211-4BF8-B99B-F684E83AD250Q38544740-6EC473A4-C6C6-4B2B-9413-8378436381B3
P2860
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Histone deacetylase inhibitors ...... for their anti-cancer effect.
@en
Histone deacetylase inhibitors ...... for their anti-cancer effect.
@nl
type
label
Histone deacetylase inhibitors ...... for their anti-cancer effect.
@en
Histone deacetylase inhibitors ...... for their anti-cancer effect.
@nl
prefLabel
Histone deacetylase inhibitors ...... for their anti-cancer effect.
@en
Histone deacetylase inhibitors ...... for their anti-cancer effect.
@nl
P2860
P1476
Histone deacetylase inhibitors ...... for their anti-cancer effect.
@en
P2093
H Miles Prince
Michael Dickinson
P2860
P2888
P356
10.1007/S10637-010-9596-Y
P478
28 Suppl 1
P577
2010-12-01T00:00:00Z
2010-12-14T00:00:00Z